Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ILMN 
Illumina Inc (ILMN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ILMN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $111.95
1 Year Target Price $111.95
| 7 | Strong Buy |
| 5 | Buy |
| 11 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.88% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.51B USD | Price to earnings Ratio 12.03 | 1Y Target Price 111.95 |
Price to earnings Ratio 12.03 | 1Y Target Price 111.95 | ||
Volume (30-day avg) 25 | Beta 1.43 | 52 Weeks Range 68.70 - 156.66 | Updated Date 09/15/2025 |
52 Weeks Range 68.70 - 156.66 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 8.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 29.34% | Operating Margin (TTM) 21.15% |
Management Effectiveness
Return on Assets (TTM) 8.84% | Return on Equity (TTM) 68.06% |
Valuation
Trailing PE 12.03 | Forward PE 19.19 | Enterprise Value 16062944000 | Price to Sales(TTM) 3.62 |
Enterprise Value 16062944000 | Price to Sales(TTM) 3.62 | ||
Enterprise Value to Revenue 3.75 | Enterprise Value to EBITDA 9 | Shares Outstanding 153700000 | Shares Floating 149331846 |
Shares Outstanding 153700000 | Shares Floating 149331846 | ||
Percent Insiders 0.19 | Percent Institutions 103.37 |
Upturn AI SWOT
Illumina Inc
Company Overview
History and Background
Illumina Inc. was founded in April 1998 and is headquartered in San Diego, California. It is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company's technology is used in a wide range of applications, including genomics, personalized medicine, and drug discovery.
Core Business Areas
- Core Genomics and Sequencing: Provides sequencing systems, consumables, and services that enable researchers to analyze genetic material and understand biological processes.
- Clinical Genomics: Offers solutions for clinical applications, including non-invasive prenatal testing (NIPT), oncology, and genetic disease diagnostics.
- Applied Genomics: Focuses on applications in agrigenomics, forensics, and other fields, providing tools and services for genetic analysis.
Leadership and Structure
Illumina is led by CEO Jacob Thaysen. The company has a traditional corporate structure with a board of directors and various functional departments, including research and development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Market Share (%): 75
- NovaSeq Series: High-throughput sequencing systems for large-scale genomic research. Illumina holds a significant market share in high-throughput sequencing. Competitors include PacBio and Oxford Nanopore.
- Market Share (%): 60
- NextSeq Series: Mid-throughput sequencing systems for a variety of applications, including clinical research and diagnostics. Competitors include Thermo Fisher Scientific.
- Market Share (%): 40
- iSeq Series: Low-throughput sequencing systems for small-scale research and targeted sequencing. Competitors include Qiagen.
Market Dynamics
Industry Overview
The genomics industry is experiencing rapid growth driven by technological advancements, increasing demand for personalized medicine, and declining sequencing costs. The market is competitive, with several key players offering sequencing platforms and related services.
Positioning
Illumina holds a dominant position in the sequencing market due to its advanced technology, large installed base, and strong brand recognition. Illumina has a competitive edge due to the price point of its products.
Total Addressable Market (TAM)
The total addressable market is estimated to be around $50 billion, with significant growth potential. Illumina is well-positioned to capture a large share of this market due to its leading technology and market presence.
Upturn SWOT Analysis
Strengths
- Dominant market share
- Advanced sequencing technology
- Strong brand reputation
- Large installed base
- Extensive product portfolio
Weaknesses
- High product prices can be a barrier to entry for some customers
- Dependence on a few key suppliers
- Past failed acquisition attempts such as the Graile acquisition.
- Regulatory environment is highly restrictive.
Opportunities
- Expanding applications in clinical diagnostics
- Growth in emerging markets
- Increasing adoption of personalized medicine
- Development of new sequencing technologies
- Expansion into other life science fields
Threats
- Increasing competition from other sequencing companies
- Potential for disruptive technologies
- Regulatory hurdles
- Economic downturns impacting research funding
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- TMO
- PACB
- QGEN
Competitive Landscape
Illumina holds a dominant position in the market due to its advanced technology and extensive product portfolio. However, competitors are developing new technologies and offering lower-cost solutions, which could erode Illumina's market share over time.
Major Acquisitions
GRAIL
- Year: 2021
- Acquisition Price (USD millions): 7100
- Strategic Rationale: The acquisition of GRAIL was intended to accelerate the development and commercialization of early cancer detection tests. The deal has been fraught with regulatory issues.
Growth Trajectory and Initiatives
Historical Growth: Illumina has experienced significant growth over the past decade, driven by technological advancements and increasing demand for sequencing. Growth has slowed in recent years.
Future Projections: Analysts project moderate revenue growth for Illumina in the coming years, driven by expansion in clinical diagnostics and emerging markets.
Recent Initiatives: Illumina is focused on developing new sequencing technologies, expanding its product portfolio, and growing its presence in clinical diagnostics.
Summary
Illumina is a dominant player in the genomics industry with advanced technology and a strong brand. However, the company faces increasing competition, regulatory hurdles, and the costs of its recent acquisition. Revenue growth has slowed recently, and net income has suffered. The company needs to overcome regulatory hurdles with GRAIL and continue innovating to maintain its leading position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Illumina Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2000-07-28 | CEO & Director Mr. Jacob Thaysen Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 8970 | Website https://www.illumina.com |
Full time employees 8970 | Website https://www.illumina.com | ||
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.